Teva Pharmaceutical Industries Ltd. TEVA
39.19
(1.03)
(2.56%)
as of 25 Sep
- Market cap
- $46.9B
- P/E
- 62.2×
Follow TEVA
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 9.69% | 21.58% | 21.21% | 10.44% |
+8 more TTM periods Free account |
|
| 1.77% | 3.99% | 3.52% | 1.74% | ||
ROIC |
4.58% | 6.77% | 6.37% | 7.84% | |
Return on Tangible Assets |
34.62% | 37.48% | 30.85% | 11.74% | |
Average Days of Receivables |
73.63 | 71.38 | 78.44 | 82.90 | |
Free Cash Flow per Share |
1.20 | 1.06 | 1.03 | 0.54 | |
Free Cash Flow |
1,401.00 | 1,231.00 | 1,182.00 | 616.00 | |
Capital Expenditures |
(497.00) | (483.00) | (467.00) | (450.00) | |
Piotroski F-Score |
7.00 | 7.00 | 8.00 | 8.00 | |
| Other line items | |||||
Cash ROIC |
6.78% | 5.99% | 5.83% | 4.06% | |
Accounts Receivable Turnover |
4.91 | 5.12 | 5.10 | 4.61 | |
Accounts Payable Turnover |
3.15 | 3.40 | 3.52 | 3.54 | |
Inventory Turnover |
2.45 | 2.59 | 2.69 | 2.30 | |
Average Days of Payables |
120.65 | 113.93 | 111.04 | 102.65 | |
Days of Inventory on Hand |
142.82 | 139.38 | 139.46 | 144.84 | |
Tax Rate |
(0.02) | 0.14 | 0.15 | (0.27) | |
Research and Development Expense of Revenue |
9.90% | 5.69% | 5.87% | 5.93% | |
Selling, General and Administrative Expense of Revenue |
23.85% | 23.37% | 23.02% | 22.68% | |
Share Based Compensation of Revenue |
0.97% | 0.96% | 0.91% | 0.83% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
2.68 | 1.10 | 1.17 | 1.50 | |
Depreciation/Fixed assets |
0.25 | 0.25 | 0.25 | 0.21 | |
Capex/Depreciation |
(0.50) | (0.48) | (0.47) | (0.45) | |
Revenue per Share |
14.86 | 15.01 | 15.07 | 14.63 | |
Operating CF per Share |
1.63 | 1.48 | 1.44 | 0.93 | |
Capex per Share |
(0.43) | (0.42) | (0.41) | (0.39) | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.03 | |
Net Profit Margin |
4.08% | 9.02% | 8.17% | 4.24% |
Columns are period end dates